Evidence map›Paper›PMID 42089434›Full record

ArticleCancer2026

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Jennifer Marvin-Peek, Courtney D DiNardo, Sanam Loghavi, Farhad Ravandi, Gautam Borthakur, Naval G Daver, Tapan M Kadia, Elias Jabbour, Andrew Dunbar, Guilin Tang and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Jennifer Marvin-PeekDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-9595-1279
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-9003-0390
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Naval G DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-7103-373X
Tapan M KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-9892-9832
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-4465-6119
Andrew DunbarDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guilin TangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-9482-4806
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-2983-2738
Fadi G HaddadDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-9702-8485
Hussein A AbbasDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Eitan KuglerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0009-0005-1539-1766
Abhishek MaitiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ghayas C IssaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-8027-9659
Kapil BhallaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-1670-6513
Yesid AlvaradoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elizabeth J ShpallDepartment of Stem Cell Transplant & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Uday PopatDepartment of Stem Cell Transplant & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-7592-2224
Jeremy RamdialDepartment of Stem Cell Transplant & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-8984-3420
Richard E ChamplinDepartment of Stem Cell Transplant & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-1908-3307
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-3631-2482
Jayastu SenapatiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-6831-2567

Funding

T32 Training Grant CA009666University of Texas MD Anderson Cancer Center Leukemia Support Grant CA016672University of Texas MD Anderson Cancer Center Specialized Program of Research Excellence C1100632
6 · The paper itself

Abstract

backgroundASXL1 mutations (ASXL1

methodsA retrospective analysis in 554 adults with newly diagnosed AML treated with LIT was conducted, stratified by ASXL1 mutation status and treatment backbone.

resultsWithin the European LeukemiaNet 2024 favorable-risk strata, ASXL1

conclusionsCollectively, these findings suggest that ASXL1

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteMutationRepressor ProteinsAdultAgedBridged Bicyclo Compounds, HeterocyclicFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesSulfonamidesASXL1 protein, humanBridged Bicyclo Compounds, HeterocyclicRepressor ProteinsSulfonamidesvenetoclaxacute myeloid leukemiaAMLASXL1low‐intensity therapyvenetoclax

Identifiers

PMID42089434
PMCPMC13147490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.